Glaukos announces positive three-year Epioxa Phase 3 extension results
Glaukos said topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating Epioxa in keratoconus showed positive three-year outcomes, described as durable.
Story updates
08:05:36 PM UTC
SquawkNews
Glaukos reported long-term Phase 3 extension results for Epioxa in keratoconus, showing a sustained 1.9D Kmax improvement at 3 years and no serious adverse events in treated eyes.Material DetailsContext by AI AnalystThis is late-stage confirmation reinforcing previously reported Phase 3 outcomes an…
08:08:33 PM UTC
SquawkNews
GKOS - Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus